VIVES is a multi-sector fund that invests in projects with a positive societal impact
Botalys has developed a vertical farming technology that enables the production of rare plants and high-value ingredients for the food supplement, cosmetics, and pharmaceutical industries. This...
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation biologics for severe immune-mediated inflammatory diseases. Bionyra’s best-in-class mono and multispecific...
ViroVet is a pioneering company developing innovative technologies to combat viral diseases in livestock. They focus on antiviral drugs for complex respiratory illnesses and novel vaccines to protect...
Vincent Mouret, Chairman of the Board of Cissoid:
"As Chairman of the board of Cissoid, I’ve been working closely to VIVES for the last 10 years. I have really appreciated VIVES involvement and...
Georges Caron, past CEO Keemotion:
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with the...
Michel Detheux, CEO iTeos Therapeutics:
"VIVES has played a unique dual role as incubator and spin off investor during the inception of iTeos not only to shape the equity story, but also to connect...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to